Skip to main content
PMC home page
Experimental and Therapeutic Medicine logoLink to Experimental and Therapeutic Medicine
. 2014 Jul 29;8(4):1259–1262. doi: 10.3892/etm.2014.1869

Clinical significance of interleukin-6, tumor necrosis factor-α and high-sensitivity C-reactive protein in neonates with hypoxic-ischemic encephalopathy

YUN SHANG 1, LINA MU 1, XIXIA GUO 2, YUHUA LI 3, LIMIN WANG 2, WEIHONG YANG 1, SHUJUN LI 4,✉, QIONG SHEN 5
PMCID: PMC4151692  PMID: 25187835

Abstract

The present study aimed to investigate the potential roles of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (Hs-CRP) in the progression and prognosis of neonatal hypoxic-ischemic encephalopathy (HIE). The observation group comprised 74 neonates with HIE and the control group comprised 74 healthy neonates. The serum levels of IL-6, TNF-α and Hs-CRP were measured in the patients with HIE and the normal control infants. The correlations between the variances in the levels of these inflammatory cytokines and the different clinical gradings and prognoses of the disease were analyzed. The data revealed significant upregulation of the serum levels of IL-6, TNF-α and Hs-CRP in patients with HIE. The increase in the levels of these inflammatory mediators correlated with the severity of the disease and also had a positive correlation with the prognosis of the disease. In conclusion, high levels of IL-6, TNF-α and Hs-CRP were observed in neonatal patients with HIE. Thus, these inflammatory mediators may play a role in the progression and prognosis of the disease.

Keywords: hypoxic-ischemic encephalopathy, interleukin-6, tumor necrosis factor-α, high-sensitivity C-reactive protein, prognosis

Introduction

Neonatal hypoxic-ischemic encephalopathy (HIE) causes high infant mortality and long-term morbidity rates (1–3). HIE occurs in ~1–3 per 1,000 full-term infants and in almost 60% of premature newborns. Approximately 15–20% of affected newborns succumb within the postnatal period (4) and an additional 25% develop severe and permanent neuropsychological handicaps (5), including cerebral palsy, seizures, visual impairment, mental retardation, learning disabilities and epilepsy. Following the infiltration of circulating monocytes, neutrophils and T-cells in neonates, cerebral ischemia initiates an immediate innate immune response that may occur minutes following insult. This in turn exacerbates damage to the brain with a large accumulation of inflammatory cytokines (6–8). However, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), two inflammatory cytokines that are accumulated during cerebral ischemia, play a protective role in the incidence of HIE (9,10). Secreted by T cells, B cells and macrophages, IL-6 and TNF-α may be enriched during the progression of stress (11,12). High-sensitivity C-reactive protein (Hs-CRP), an acute-phase protein, is secreted by the liver in response to factors released by macrophages and fat cells. It is a sensitive marker of inflammatory reactions, since its levels rise in response to inflammation (13,14).

To date, several studies have revealed the association of inflammatory cytokines with the process of HIE (11–13); however, it remains unclear as to whether these cytokines play a role in the progression and prognosis of the disease. The current study analyzed the levels of IL-6, TNF-α and Hs-CRP among the different clinical gradings of HIE and further investigated the correlation between the changes in the levels of these inflammatory cytokines and the clinical prognosis of the disease.

Subjects and methods

Patients

A total of 74 patients with HIE, admitted to The First Affiliated Hospital of Xinxiang Medical University (Weihui, China) hospital between June 2010 and June 2013, were involved in the current study. All patients had been previously diagnosed and clinically graded based on encephalic computed tomography scans and the clinical determination criteria for HIE (15) (Table I). The control group comprised 74 healthy newborns. There were no statistically significant differences between the HIE and control groups in terms of gender, gestational age and weight (P>0.05). All patients with HIE were classified by clinical grading and comprised 31 individuals with mild, 26 with moderate and 17 with severe HIE. There was no statistically significant difference among the different gradings in terms of gender, gestational age and weight (P>0.05). Furthermore, the patients with HIE were divided into good and poor prognosis groups with 32 and 42 individuals in each group, respectively. Once again, there was no statistically significant difference between the groups in terms of gender, gestational age and weight (P>0.05). The present study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of The First Affiliated Hospital of Xinxiang Medical University. Written informed consent was provided by the legal guardians of all participants.

Table I.

Clinical information of the patients.

Group Cases Gender Gestational age, weeks (mean±SD) Weight, g (mean±SD)
Male Female
Control 74 44 30 39.5±2.9 3418±524
HIE 74 42 32 39.6±2.7 3591±619
Open in a new tab

HIE, hypoxic-ischemic encephalopathy; SD, standard deviation.

Treatment methods

All patients were administered narcotic, anti-acidosis, encephalic hypotensive and antioxidant drugs. Hyperbaric oxygen therapy was also performed daily on all patients.

Enzyme-linked immunosorbent assay (ELISA) and radioimmunometric assay (RIA)

The serum levels of IL-6 and TNF-α were evaluated by ELISA using commercially-available kits (R&D Systems, Minneapolis, MN, USA). A RIA was carried out to detect the serum levels of Hs-CRP using a commercially-available kit (Jokoh Co., Ltd., Tokyo, Japan). The assays were performed following the manufacturers’ instructions.

Statistical analysis

Computerized statistical analyses were performed using SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as mean ± standard deviation. The variances in the levels of the inflammatory cytokines between the controls and patients were analyzed using the Student’s t-test. The comparisons of these parameters among the different grading groups were calculated using analysis of variance (ANOVA) and multiple comparison tests. The correlation between the change in the levels of the inflammatory cytokines and the clinical grading and prognosis of the disease was examined by Spearman’s correlation analysis. In all statistical analyses, a two-tailed P-value ≤0.05 was considered to indicate a statistically significant difference.

Results

Serum concentrations of IL-6, TNF-α and Hs-CRP

The serum levels of IL-6, TNF-α and Hs-CRP were detected. The levels of IL-6 (39.94±4.46 pg/ml; P<0.05), TNF-α (97.00±5.97 pg/ml; P<0.05) and Hs-CRP (11.93±1.91 mg/l; P<0.05) were significantly higher in the patients with HIE compared with the respective values in the control group, IL6 (9.18±1.27 pg/ml), TNF α (17.20±1.26 pg/ml) and Hs CRP (0.51±0.18 mg/l) (Fig. 1).

Figure 1.

Figure 1

Open in a new tab

Concentrations of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (Hs-CRP) in the serum. Serum levels of IL-6, TNF-α and Hs-CRP in patients with hypoxic-ischemic encephalopathy (HIE) and normal control infants were evaluated by enzyme-linked immunosorbent assay (Il-6 and TNF-α) or radioimmunometric assay (Hs-CRP).

Comparison of the serum levels of IL-6, TNF-α and Hs-CRP in patients with different clinical gradings

The present investigation revealed that the upregulation of inflammatory cytokines was accompanied by deterioration of the disease. As shown in Fig. 2, the levels of IL-6, TNF-α and Hs-CRP in the moderate and severe patient groups were significantly higher compared with those in the mild group (P<0.05). Furthermore, there was a significant upregulation of the cytokines in the severe group compared with those in the moderate group (P<0.05).

Figure 2.

Figure 2

Open in a new tab

Comparison of the serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (Hs-CRP) in patients with hypoxic-ischemic encephalopathy (HIE) with different clinical gradings. Serum levels of IL-6, TNF-α and Hs-CRP were analyzed among the groups of patients with mild, moderate or severe HIE.

Comparison of the serum levels of IL-6, TNF-α and Hs-CRP in patients with different prognoses

The levels of IL-6, TNF-α and Hs-CRP in patients with either a poor or good prognosis were further analyzed. Significant upregulation of the levels of IL-6 (37.75±4.24 pg/ml; P<0.05), TNF-α (90.23±7.37 pg/ml; P<0.05) and Hs-CRP (9.71±2.14 mg/l; P<0.05) were observed in patients who had a poor prognosis compared with those in the patients who had a good prognosis, IL 6 (19.59±2.94 pg/ml), TNF α (44.32±4.84 pg/ml) and Hs CRP (5.99±0.99 mg/l) (Fig. 3).

Figure 3.

Figure 3

Open in a new tab

Comparison of the serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (Hs-CRP) in patients with hypoxic-ischemic encephalopathy (HIE) with different prognoses. Serum levels of IL-6, TNF-α and Hs-CRP were analyzed in patients with a poor or good prognosis.

Correlation between the changes in the levels of inflammatory cytokines and the clinical grading and prognosis of the disease

Based on the variations in the levels of IL-6, TNF-α and Hs-CRP in patients with HIE, it is hypothesized that they may play a role in the progression and prognosis of the disease. A correlation analysis between these changes and the disease progression and prognosis was carried out. Notably, positive correlations were identified between the levels of IL-6, TNF-α and Hs-CRP and the clinical grading (r=1.071, 0.811, 0.704, respectively; P<0.05) and prognosis (r=1.071, 0.811, 0.704, respectively; P<0.05) of the disease.

Discussion

HIE occurring in fetuses and neonates is a major cause of acute mortality and chronic neurological disability in surviving individuals (16). An increasing number of studies have indicated that there is a complicated correlation between HIE and the immune system (17,18). Cytokines are activated in glial cells and astrocytes in the central nervous system (CNS) and are released in response to brain damage. In return, the activated cytokines regulate the activity of the immune system. Thus, inflammatory cytokines play an important role in brain inflammation caused by the occurrence of HIE. IL-6 is a multifunctional immune mediator that regulates cellular immunity and the inflammatory response. Being a pro- and anti-inflammatory factor, IL-6 has caused controversy in studies investigating its role in HIE in previous years. The ambiguous effects of IL-6 on the CNS have been observed not only in animal models, but also in human studies. The overexpression of IL-6 in animals or its increased release in the brain has neurotoxic effects and may trigger an inflammatory response cascade. By contrast, IL-6 deficient mice demonstrate neuroprotective and anticonvulsive characteristics (19,20). Furthermore, higher levels of IL-6 have been observed in infants with HIE than in normal infants and the concentration of IL-6 has been found to be significantly associated with the severity of HIE and the neurodevelopmental outcome at two years of age (21). Secreted by macrophages, TNF-α is accumulated under stress and manipulates tissue injury. In the CNS, TNF-α is secreted by microglia and astrocytes. Previous studies have indicated that TNF-α may act in a concentration-dependent manner. TNF-α has been reported to play an immunoprotective role in HIE at a low concentration, but exert a proinflammatory effect at a high concentration (22,23). Hs-CRP is an acute-phase protein secreted at a low level by the liver under normal circumstances. It is a sensitive marker of inflammatory reactions since its levels increase in response to inflammation when the body is under stress (24,25).

The present study revealed that the serum levels of IL-6, TNF-α and Hs-CRP in patients with HIE were upregulated when compared with those in the normal controls. The increased levels of Hs-CRP indicate the presence of an acute inflammatory response in the patients; furthermore, the high levels of IL-6 and TNF-α may have evoked an inflammatory response cascade and caused further damage in the brain.

In order to detect the potential correlation between the inflammatory factors and the different clinical gradings of the disease, the serum levels of IL-6, TNF-α and Hs-CRP in patients with different clinical gradings were analyzed. The results demonstrated a correlation between the upregulation of these cytokines and the severity of the disease. Notably, a positive correlation between the grading severity and the different cytokines was identified. Thus, patients with greater inflammatory responses suffered from a severe progression of the disease.

Since a quarter of the patients who survive with HIE suffer from a variety of neuropsychological disabilities, the possible correlation between these mediators and the prognosis of the disease was investigated. Notably, a positive correlation between the different inflammatory factors and the prognosis of the disease was identified.

In conclusion, the current study highlighted the presence of high levels of IL-6, TNF-α and Hs-CRP in patients with HIE and the potential role of these inflammatory mediators in the progression and prognosis of the disease. HIE not only induces the expression of cytokines in the brain but also changes the levels of the peripheral cytokines, which in turn exacerbates the disease in the brain and other tissues.

References

  • 1.Zhang P, Cheng GQ. Research progress in mild hypothermia treatment of neonatal hypoxic-ischemic encephalopathy. Zhongguo Dang Dai Er Ke Za Zhi. 2013;15:918–922. (In Chinese) [PubMed] [Google Scholar]
  • 2.Filippi L, Fiorini P, Daniotti M, et al. Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI) BMC Pediatr. 2012;12:144. doi: 10.1186/1471-2431-12-144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;1:CD003311. doi: 10.1002/14651858.CD003311.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lai MC, Yang SN. Perinatal hypoxic-ischemic encephalopathy. J Biomed Biotechnol. 2011;2011:609813. doi: 10.1155/2011/609813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics. 1997;100:1004–1014. doi: 10.1542/peds.100.6.1004. [DOI] [PubMed] [Google Scholar]
  • 6.Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin. 2013;34:1121–1130. doi: 10.1038/aps.2013.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bonestroo HJ, Nijboer CH, van Velthoven CT, et al. Cerebral and hepatic inflammatory response after neonatal hypoxia-ischemia in newborn rats. Dev Neurosci. 2013;35:197–211. doi: 10.1159/000346685. [DOI] [PubMed] [Google Scholar]
  • 8.Pimentel VC, Gomes JL, Zanini D, et al. Evaluation of acetylcholinesterase and adenosine deaminase activities in brain and erythrocytes and proinflammatory cytokine levels in rats submitted to neonatal hypoxia-ischemia model. Mol Cell Biochem. 2013;378:247–255. doi: 10.1007/s11010-013-1615-9. [DOI] [PubMed] [Google Scholar]
  • 9.Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1998;18:176–179. doi: 10.1097/00004647-199802000-00008. [DOI] [PubMed] [Google Scholar]
  • 10.Girard S, Sébire H, Brochu ME, et al. Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or hypoxic-ischemic injuries. Brain Behav Immun. 2012;26:1331–1339. doi: 10.1016/j.bbi.2012.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Aly H, Khashaba MT, El-Ayouty M, El-Sayed O, Hasanein BM. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev. 2006;28:178–182. doi: 10.1016/j.braindev.2005.06.006. [DOI] [PubMed] [Google Scholar]
  • 12.Silveira RC, Procianoy RS. Interleukin-6 and tumor necrosis factor-alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. J Pediatr. 2003;143:625–629. doi: 10.1067/S0022-3476(03)00531-6. [DOI] [PubMed] [Google Scholar]
  • 13.Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med. 2011;123:114–119. doi: 10.3810/pgm.2011.01.2252. [DOI] [PubMed] [Google Scholar]
  • 14.Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397–408. doi: 10.1016/j.jacc.2013.05.016. [DOI] [PubMed] [Google Scholar]
  • 15.Li XH. Diagnosis and therapy of hypoxic-ischemic encephalopathy in newborn infants in China. J Appl Clin Pediatr. 2010;25:1037–1039. [Google Scholar]
  • 16.van Laerhoven H, de Haan TR, Offringa M, Post B, van der Lee JH. Prognostic tests in term neonates with hypoxic-ischemic encephalopathy: a systematic review. Pediatrics. 2013;131:88–98. doi: 10.1542/peds.2012-1297. [DOI] [PubMed] [Google Scholar]
  • 17.Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin. 2013;34:1121–1130. doi: 10.1038/aps.2013.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Jenkins DD, Lee T, Chiuzan C, et al. Altered circulating leukocytes and their chemokines in a clinical trial of therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatr Crit Care Med. 2013;14:786–795. doi: 10.1097/PCC.0b013e3182975cc9. [DOI] [PubMed] [Google Scholar]
  • 19.Ali C, Nicole O, Docagne F, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab. 2000;20:956–966. doi: 10.1097/00004647-200006000-00008. [DOI] [PubMed] [Google Scholar]
  • 20.Westberg JA, Serlachius M, Lankila P, et al. Hypoxic preconditioning induces neuroprotective stanniocalcin-1 in brain via IL-6 signaling. Stroke. 2007;38:1025–1030. doi: 10.1161/01.STR.0000258113.67252.fa. [DOI] [PubMed] [Google Scholar]
  • 21.Chiesa C, Pellegrini G, Panero A, et al. Umbilical cord interleukin-6 levels are elevated in term neonates with perinatal asphyxia. Eur J Clin Invest. 2003;33:352–358. doi: 10.1046/j.1365-2362.2003.01136.x. [DOI] [PubMed] [Google Scholar]
  • 22.Wang Y, Cao M, Liu A, et al. Changes of inflammatory cytokines and neurotrophins emphasized their roles in hypoxic-ischemic brain damage. Int J Neurosci. 2013;123:191–195. doi: 10.3109/00207454.2012.744755. [DOI] [PubMed] [Google Scholar]
  • 23.Oygür N, Sönmez O, Saka O, Yeğin O. Predictive value of plasma and cerebrospinal fluid tumour necrosis factor-alpha and interleukin-1 beta concentrations on outcome of full term infants with hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 1998;79:F190–F193. doi: 10.1136/fn.79.3.f190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Guo AS, Li AH, Chen X, Chen WG, Sun L. Effect of acupoint catgut embedding on motor function and serum high sensitivity C-reactive protein and IL-6 levels in patients with acute cerebral infarction. Zhen Ci Yan Jiu. 2013;38:224–228. (In Chinese) [PubMed] [Google Scholar]
  • 25.Chen S, Martens-Lobenhoffer J, Weissenborn K, et al. Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. J Neuroinflammation. 2012;9:251. doi: 10.1186/1742-2094-9-251. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Experimental and Therapeutic Medicine are provided here courtesy of Spandidos Publications

RESOURCES